For the last several years, American cholesterol care operated largely without explicit targets. The 2018 guideline emphasized statin intensity and percentage reductions — take the right dose, lower LDL by the right percent, and the exact landing number mattered less. The 2026 dyslipidemia guideline reverses that: specific, value-based LDL cholesterol goals are back, and they are lower than any prior American guideline.
The New Targets
- Very high-risk patients with established cardiovascular disease — a history of heart attack, stroke, or significant arterial disease plus additional risk features: LDL-C below 55 mg/dL, with a companion non-HDL cholesterol goal below 85 mg/dL.
- Other patients with established cardiovascular disease: LDL-C below 70 mg/dL — though the guideline notes most patients with prior events will qualify for the stricter under-55 goal.
- High-risk primary prevention (no prior event, but 10-year risk of 10% or more): LDL-C below 70 mg/dL, non-HDL below 100 mg/dL.
- Borderline-to-intermediate risk (10-year risk of 3–10%): LDL-C below 100 mg/dL, non-HDL below 130 mg/dL.
Treatment decisions start earlier too: the guideline says lipid-lowering therapy can be considered once 10-year risk reaches just 3%, and should be considered at 5%.
Why Targets Came Back
Because the evidence kept pointing the same direction. Trial after trial showed that patients who achieve lower LDL levels have fewer heart attacks and strokes, with benefit continuing well below the old thresholds and no signal of harm from very low LDL. Percent-based dosing left too many patients "on therapy" but far from optimal — technically adherent, still exposed. A number gives you and your cardiologist something concrete to manage toward, and a clear trigger to intensify treatment when you're not there.
"My Statin Is Working" Isn't the Whole Answer Anymore
Under the new framework, the question is no longer are you on a statin? It's what is your LDL, and is it at your goal? A patient on a moderate statin dose sitting at an LDL of 88 after a heart attack is not at goal — they're 33 points away. Getting there might mean a higher-intensity statin, adding ezetimibe, or one of the newer agents. The point of a target is that "close" is measurable, and so is "not close."
The Fine Print: Non-HDL and ApoB
The guideline pairs each LDL goal with a non-HDL cholesterol goal (your total cholesterol minus HDL — a broader measure of all atherogenic particles), and endorses selective use of apolipoprotein B testing. ApoB counts the actual number of artery-damaging particles, and the guideline notes treatment can reasonably be intensified when apoB remains elevated even if LDL looks at goal — a scenario that is surprisingly common in patients with diabetes, metabolic syndrome, or high triglycerides.
Know Your Number, Know Your Goal
Every patient at Cardiolucent leaves with both: current numbers from an advanced lipid panel (including apoB), and an explicit goal based on their individual risk. Our approach to guideline-directed medical therapy means your regimen is actively managed toward the 2026 targets — reviewed, adjusted, and re-checked — not set once and left alone.
Source: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia — a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, published in Circulation and the Journal of the American College of Cardiology, March 2026.